Scientists have identified the specific immune cells that travel from inflamed skin to joints, and more importantly, why some people's joints can stop this inflammation while others cannot. Roughly 20 to 30 percent of people with psoriasis eventually develop psoriatic arthritis, a painful joint condition that can cause lasting bone damage if left untreated. For years, doctors puzzled over why the disease progressed in some patients but not others. Now, researchers from Friedrich-Alexander-Universität Erlangen-Nürnberg have uncovered the cellular journey that explains this mystery, opening doors to early detection and prevention. How Do Immune Cells Travel From Skin to Joints? When psoriasis inflames the skin, it triggers the formation of specialized immune precursor cells. These cells don't stay put in the skin. Instead, they enter the bloodstream and travel throughout the body, eventually reaching the joints. The research team found that this migration happens in people who go on to develop psoriatic arthritis, but the presence of these cells alone doesn't automatically cause joint inflammation. "These cells can migrate from the skin to the bloodstream and from there to the joints," explained Dr. Simon Rauber, head of the working group at the Department of Medicine 3. "However, the mere migration of immune cells into the joint is not sufficient to trigger inflammation there." Dr. Simon Rauber, Head of Working Group, Department of Medicine 3, Friedrich-Alexander-Universität Erlangen-Nürnberg This distinction is crucial. The journey from skin to joint is only part of the story. What happens once these cells arrive determines whether joint disease develops. Why Do Some Joints Develop Inflammation While Others Don't? Once immune cells reach the joints, they interact with fibroblasts, which are connective tissue cells that normally act as protectors, maintaining balance and defending the joint from inflammation. In people who develop psoriatic arthritis, this protective response breaks down. The fibroblasts fail to keep the inflammatory cells in check, allowing inflammation to take hold. "The protective function of these connective tissue cells is usually considerably reduced in people who develop psoriatic arthritis. As a result, the inflammatory cells that enter the joint cannot be brought into check, and go on to trigger an inflammatory reaction in the joint," stated Prof. Dr. Andreas Ramming, team leader and deputy head of department. Prof. Dr. Andreas Ramming, Team Leader and Deputy Head of Department, Department of Medicine 3, Friedrich-Alexander-Universität Erlangen-Nürnberg This discovery explains the puzzle that has long frustrated rheumatologists. Two patients with psoriasis might have the same immune cells traveling to their joints, but only one develops arthritis because their joint's protective mechanisms are compromised. How to Identify Patients at Risk Before Joint Damage Occurs The research team made another important discovery: these migratory immune cells can be detected in the blood before joint inflammation begins. This opens the possibility of identifying high-risk patients earlier than ever before, potentially preventing psoriatic arthritis rather than treating damage after it has already occurred. - Early Blood Testing: Doctors could screen for the presence of these specific immune cells in the bloodstream to identify patients at higher risk of developing psoriatic arthritis before symptoms appear. - Preventive Treatment Strategies: Future therapies may target these immune cells before they reach the joints, stopping inflammation at the source rather than managing it after joint damage has begun. - Personalized Monitoring: Patients identified as high-risk could receive closer monitoring and early intervention, potentially preventing the permanent bone and joint damage that makes psoriatic arthritis so debilitating. The implications are significant for the roughly 7.5 million Americans with psoriasis. If doctors can identify the 20 to 30 percent who are at risk of developing joint disease, they could intervene before irreversible damage occurs. This shift from treating established disease to preventing it represents a major advance in rheumatology. The research was funded by the German Research Foundation, the European Research Council, and the Interdisciplinary Center for Clinical Research in Erlangen, and was published in Nature Immunology. The findings suggest that the next generation of psoriatic arthritis treatment may focus less on managing inflammation after it develops and more on stopping the cellular journey that triggers it in the first place.
